论文部分内容阅读
作者于1982年冬季(1～3月)对37例哮喘儿童(男26例,女11例,7～15岁,平均11.6岁),观察了鼻内给与Budesonide(Bud)对鼻症状、呼吸型式与哮喘的影响。受试者按美国胸科学会标准确诊哮喘,除外鼻中隔弯曲、鼻息肉或增大的腺样增殖体;鼻塞与口呼吸持续至少3个月;经皮肤划痕与放射过敏原吸附试验(RAST)肯定为过敏反应,最常见的过敏原为屋尘螨、动物皮屑与花粉;试验前5个月内未曾全身或局部应用皮质类同醇。采用双盲平行法设计研究,经2周观察期,随机分成Bud组(18例)与安慰剂组(19例),治疗期为4周,Bud以鼻内喷
In the winter of 1982 (January-March), 37 children with asthma (26 males and 11 females, aged 7 to 15 years, mean 11.6 years) were enrolled in this study. Intranasal administration of Budesonide (Bud) to nasal symptoms, Type and the impact of asthma. Subjects were diagnosed with asthma by the American Thoracic Society criteria, except for nasal septum flexion, nasal polyps, or increased adenoid proliferation; nasal congestion and mouth respiration for at least 3 months; transdermal scratch and radioimmunoassay (RAST) Certainly allergic reactions, the most common allergens are house dust mites, animal dander and pollen; no systemic or topical corticosteroid alcohol was used during the first 5 months of the trial. The study was designed by double-blind parallel method and divided into Bud group (n = 18) and placebo group (n = 19) after 2 week observation period. The treatment period was 4 weeks.